the team



Established in 2016, BiVictriX Therapeutics Ltd is a North West based Biotech focused on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer.

Through the company’s novel “Dual Targeting Approach”, BiVictriX aims to challenge the conventional ADC therapeutic approach by providing a step change in target selectivity.


the team

Tiffany Thorn BSc. MSc. – Chief Executive Officer

Tiffany Thorn, inventor of the company’s ‘Dual Targeting Approach’, will lead BiVictriX’s operations as CEO.

A co-founder of BiVictriX Therapeutics, Tiffany was previously Marketing and Licensing Manager at ADC Biotechnology Ltd., gaining vital experience of the ADC market and key trends in the sector, before establishing BiVictriX in August 2016.

As a HCPC registered Clinical Immunologist, Tiffany has experience of diagnosing and treating haematological malignancy within a clinical setting and spent several years carrying out this role in the NHS. During this time, Tiffany was awarded the Chief Scientific Officer’s ‘Rising Star Award’ in 2014 for recognition of her work in establishing a regional network to support NHS: Industry collaboration, which was spun out nationally. Tiffany also previously held several technical positions at RedX Pharma Plc, a drug development company focused on the Redox Switch™ technology platform.

Tiffany graduated from Lancaster University with a first class BSc Hons. In Biochemistry with Biomedicine and later gained a MSc Distinction in Clinical Immunology at the University of Manchester.

David Youngman – Non-Executive Director

David has almost 35 years’ experience in stockbroking and corporate finance and will bring corporate finance advise and strong governance practices to BiVictriX in his role as non-executive Director.

David currently holds the position of Corporate Finance Director at Acceleris Capital Ltd., part of Seneca Partners, an Investment Management and Corporate Advisory services group which specialises in the SME sector.

From May 1995 to 2009, David was Managing Director and Head of Corporate Finance at WH Ireland. During that period, WH Ireland grew from one office with a turnover of less than £1 million to 12 UK offices and an Australian subsidiary with turnover in excess of £30 million.

David, over the course of the last nine years of his stockbroking career, was responsible for a portfolio of over 60 companies admitted to AIM.

news - click on the title to read the news story


response form

BiVictriX Therapeutics Ltd.

Bio Hub, Alderley Park, Alderley Edge, Cheshire SK10 4TG, UK

+44 (0) 7908 719 566


Submitting Form...

The server encountered an error.

Form received.


Thanks for visiting bivictrix.com

On 25th May 2018, data protection regulations are changing. These changes give you more rights, including the ability to amend or withdraw how we use your data, and to ask us to see, update or remove it.

Data collected via websites, social media and apps that can be used to identify you is now covered, and also the use of this data to make decisions.

BiVictriX Therapeutics Ltd. respects your data and puts you in control.

By completing the newsletter sign up or response form or contacting us by email you agree for us to store the information you give to us on our email system and it will be used to respond to you immediately or be used to contact you at a later date.

The data collected is held securely and will not be passed onto any third parties under any circumstances unless required to by law.


Click Here to view our Privacy Policy


You can also contact us by telephone 01225 444522

All the best from BiVictriX Therapeutics Ltd.